US OptionsDetailed Quotes

LRMR241220C7500

Watchlist

0.55
-0.05-8.33%

15min DelayClose Dec 13 16:00 ET

0.55High0.55Low

Larimar Therapeutics Stock Discussion

Trytosaveabit

May 30 15:13

Update

$Larimar Therapeutics (LRMR.US)$ Reuters· 2 mins ago
Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Jaguar8

May 30 15:10

NEWS

$Larimar Therapeutics (LRMR.US)$
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
Larimar Therapeutics announced that the FDA has selected its therapy, nomlabofusp, for the START pilot program. This program aims to accelerate the development of treatments for rare diseases. Nomlabofusp is a novel protein replacement therapy targeting the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria.
The selection...

Meltyy

May 22 02:41

Clinical Updates💉
⇒ $Larimar Therapeutics (LRMR.US)$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals (CTXR.US)$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics (HALO.US)$ $Bristol-Myers Squibb (BMY.US)$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...

Jaguar8

May 20 15:08

$Larimar Therapeutics (LRMR.US)$
NEWS
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Larimar Therapeutics (Nasdaq: LRMR) announced that the FDA has removed the partial clinical hold on their nomlabofusp (CTI-1601) program, aimed at treating Friedreich’s Ataxia (FA). This decision followed the review of data from a recently completed Phase 2 dose exploration study, which included 25 mg and 50 mg cohorts. The study showed that nom...